TOPLINE:

Among US men with grade group 1 (GG1) prostate cancer, about 1 in 6 had intermediate- or high-risk disease, along with increased rates of adverse pathology and cancer-specific mortality. This finding suggests that GG1 prostate cancer should not be reclassified as noncancerous, as some experts have proposed.

METHODOLOGY:

Some experts have pushed to reclassify GG1 prostate cancer as a noncancerous entity to help reduce overtreatment. GG1 status is primarily designated via biopsy, but current guidelines recommend treatment decisions be based on a range of parameters, including prostate-specific antigen (PSA) levels, clinical stage, and tumor volume.

Arguing against reclassification, researchers analyzed how localized GG1 prostate cancer varies by National Comprehensive Cancer Net

See Full Page